329 related articles for article (PubMed ID: 28283756)
1. Dopamine, T cells and multiple sclerosis (MS).
Levite M; Marino F; Cosentino M
J Neural Transm (Vienna); 2017 May; 124(5):525-542. PubMed ID: 28283756
[TBL] [Abstract][Full Text] [Related]
2. Dopamine and T cells: dopamine receptors and potent effects on T cells, dopamine production in T cells, and abnormalities in the dopaminergic system in T cells in autoimmune, neurological and psychiatric diseases.
Levite M
Acta Physiol (Oxf); 2016 Jan; 216(1):42-89. PubMed ID: 25728499
[TBL] [Abstract][Full Text] [Related]
3. Glutamate, T cells and multiple sclerosis.
Levite M
J Neural Transm (Vienna); 2017 Jul; 124(7):775-798. PubMed ID: 28236206
[TBL] [Abstract][Full Text] [Related]
4. Instantaneous depolarization of T cells via dopamine receptors, and inhibition of activated T cells of Psoriasis patients and inflamed human skin, by D1-like receptor agonist: Fenoldopam.
Keren A; Gilhar A; Ullmann Y; Zlotkin-Frušić M; Soroka Y; Domb AJ; Levite M
Immunology; 2019 Nov; 158(3):171-193. PubMed ID: 31424569
[TBL] [Abstract][Full Text] [Related]
5. [Blockade of D1-like dopaminergic receptors suppresses Th17-cell function in multiple sclerosis].
Melnikov MV; Sviridova AA; Solodova TV; Lopatina AV; Pashenkov MV; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7. Vyp. 2):82-89. PubMed ID: 34387452
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Dopaminergic System in Autoimmunity.
Vidal PM; Pacheco R
J Neuroimmune Pharmacol; 2020 Mar; 15(1):57-73. PubMed ID: 30661214
[TBL] [Abstract][Full Text] [Related]
7. Dopaminergic receptors and adrenoceptors in circulating lymphocytes as putative biomarkers for the early onset and progression of multiple sclerosis.
Cosentino M; Zaffaroni M; Legnaro M; Bombelli R; Schembri L; Baroncini D; Bianchi A; Clerici R; Guidotti M; Banfi P; Bono G; Marino F
J Neuroimmunol; 2016 Sep; 298():82-9. PubMed ID: 27609280
[TBL] [Abstract][Full Text] [Related]
8. The Role of D
Melnikov M; Sviridova A; Rogovskii V; Kudrin V; Murugin V; Boyko A; Pashenkov M
Curr Neuropharmacol; 2022; 20(8):1632-1639. PubMed ID: 34429055
[TBL] [Abstract][Full Text] [Related]
9. Dopaminergic Therapeutics in Multiple Sclerosis: Focus on Th17-Cell Functions.
Melnikov M; Rogovskii V; Boykо A; Pashenkov M
J Neuroimmune Pharmacol; 2020 Mar; 15(1):37-47. PubMed ID: 31011885
[TBL] [Abstract][Full Text] [Related]
10. Dopaminergic modulation of CD4+CD25(high) regulatory T lymphocytes in multiple sclerosis patients during interferon-β therapy.
Cosentino M; Zaffaroni M; Trojano M; Giorelli M; Pica C; Rasini E; Bombelli R; Ferrari M; Ghezzi A; Comi G; Livrea P; Lecchini S; Marino F
Neuroimmunomodulation; 2012; 19(5):283-92. PubMed ID: 22472872
[TBL] [Abstract][Full Text] [Related]
11. Roles of dopamine receptor subtypes in mediating modulation of T lymphocyte function.
Huang Y; Qiu AW; Peng YP; Liu Y; Huang HW; Qiu YH
Neuro Endocrinol Lett; 2010; 31(6):782-91. PubMed ID: 21196914
[TBL] [Abstract][Full Text] [Related]
12. Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFalpha or both.
Besser MJ; Ganor Y; Levite M
J Neuroimmunol; 2005 Dec; 169(1-2):161-71. PubMed ID: 16150496
[TBL] [Abstract][Full Text] [Related]
13. Dopamine fails to regulate activation of peripheral blood lymphocytes from multiple sclerosis patients: effects of IFN-beta.
Giorelli M; Livrea P; Trojano M
J Interferon Cytokine Res; 2005 Jul; 25(7):395-406. PubMed ID: 16022584
[TBL] [Abstract][Full Text] [Related]
14. Dopamine induces IL-6-dependent IL-17 production via D1-like receptor on CD4 naive T cells and D1-like receptor antagonist SCH-23390 inhibits cartilage destruction in a human rheumatoid arthritis/SCID mouse chimera model.
Nakano K; Yamaoka K; Hanami K; Saito K; Sasaguri Y; Yanagihara N; Tanaka S; Katsuki I; Matsushita S; Tanaka Y
J Immunol; 2011 Mar; 186(6):3745-52. PubMed ID: 21307293
[TBL] [Abstract][Full Text] [Related]
15. Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Messina S
Small GTPases; 2020 Sep; 11(5):312-319. PubMed ID: 30043672
[TBL] [Abstract][Full Text] [Related]
16. Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.
Lieberknecht V; Junqueira SC; Cunha MP; Barbosa TA; de Souza LF; Coelho IS; Santos AR; Rodrigues AL; Dafré AL; Dutra RC
Mol Neurobiol; 2017 Mar; 54(2):1033-1045. PubMed ID: 26801190
[TBL] [Abstract][Full Text] [Related]
17. cAMP levels in lymphocytes and CD4
Cosentino M; Kustrimovic N; Ferrari M; Rasini E; Marino F
Immunology; 2018 Mar; 153(3):337-341. PubMed ID: 28940477
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic Receptor Targeting in Multiple Sclerosis: Is There Therapeutic Potential?
Melnikov M; Pashenkov M; Boyko A
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34070011
[TBL] [Abstract][Full Text] [Related]
19. Dopaminergic dysfunction is associated with IL-1β-dependent mood alterations in experimental autoimmune encephalomyelitis.
Gentile A; Fresegna D; Federici M; Musella A; Rizzo FR; Sepman H; Bullitta S; De Vito F; Haji N; Rossi S; Mercuri NB; Usiello A; Mandolesi G; Centonze D
Neurobiol Dis; 2015 Feb; 74():347-58. PubMed ID: 25511803
[TBL] [Abstract][Full Text] [Related]
20. The neurotransmitter glutamate and human T cells: glutamate receptors and glutamate-induced direct and potent effects on normal human T cells, cancerous human leukemia and lymphoma T cells, and autoimmune human T cells.
Ganor Y; Levite M
J Neural Transm (Vienna); 2014 Aug; 121(8):983-1006. PubMed ID: 24584970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
